Sign in

CIK 0001650664

  • Non-accelerated filer
  • Smaller reporting company

Editas Medicine, Inc.

Sign in to watch
Ticker
EDIT
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Incorporated
DE
Entity type
Operating
EIN
464097528
Phone
+1 617-401-9000
Business address
11 HURLEY ST., CAMBRIDGE, MA, 02141
Open-market buys, last 90 days
$0
in 0 filings
Open-market sales, last 90 days
$89,088
in 5 filings, $89K under 10b5-1 plans

Net −$89,088. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.

Date Insider Transaction Shares Price Value Owned after
2025-03-08 Lucera Erick EVP, CHIEF FINANCIAL OFFICER Grant or award · Stock Option (right to buy) +275,100 275,100
2025-03-08 Lucera Erick EVP, CHIEF FINANCIAL OFFICER Grant or award · Stock Option (right to buy) +70,000 70,000
2025-03-04 Lucera Erick EVP, CHIEF FINANCIAL OFFICER Sale 10b5-1 −4,109 $1.71 $7K 112,720
2024-05-20 Lucera Erick EVP, CHIEF FINANCIAL OFFICER Sale 10b5-1 −22,337 $5.61 $125K 116,829
2024-03-02 Lucera Erick EVP, CHIEF FINANCIAL OFFICER Grant or award +35,300 113,200
2024-03-02 Lucera Erick EVP, CHIEF FINANCIAL OFFICER Grant or award +25,966 139,166
2024-03-02 Lucera Erick EVP, CHIEF FINANCIAL OFFICER Grant or award · Stock Option (right to buy) +106,000 106,000
2023-05-17 Lucera Erick EVP, CHIEF FINANCIAL OFFICER Grant or award +77,900 77,900
2023-05-17 Lucera Erick EVP, CHIEF FINANCIAL OFFICER Grant or award · Stock Option (right to buy) +155,800 155,800

Page 1 of 1 · 9 trades